Bill · H.R. 4780· House(119-HR-4780)
USTRx Act
- Introduced
- 7/29/2025
- Last activity
- 7/29/2025 — Referred to the House Committee on Ways and Means.
- Sponsored by
- Jodey Arrington
- Cosponsors
- - 8 - 0
- Introduced
- In Committee
What this bill would do
This bill, known as the "USTRx Act," aims to address trade practices in high-income countries that the Congress believes unfairly exploit United States pharmaceutical innovation. It seeks to take action against foreign price controls that deviate from market-based policies. To achieve this, the bill establishes the position of Chief Pharmaceutical Trade Negotiator. This official is tasked with conducting negotiations, enforcing trade agreements, and advocating for United States manufacturers and consumers. Additionally, the United States Trade Representative will maintain a list of high-income countries and submit annual reports regarding their pharmaceutical trade practices. The bill also provides a mechanism for responding to adverse trade actions taken by these countries.
Yes· 3 of 9
Does this make patent and copyright rules fairer?+7
The bill aims to protect the value of United States pharmaceutical innovation against foreign exploitation.
Would business owners be better off under this?+7
The bill specifically advocates for the market access and interests of United States pharmaceutical manufacturers.
Does this make the government pay for what it commits to?+5
The bill seeks to prevent foreign price controls from unfairly shifting the costs of pharmaceutical development onto United States taxpayers.
The opposite
Does this strengthen ties with allied countries?-2
The use of trade countermeasures against high-income countries may create friction with international allies.
Who it would affect, and how
Potential Positive Impacts for People
-
Ensuring access to treatments: The bill states that combating foreign price controls is necessary to safeguard access to life-sating treatments for American patients (Section 2(a)(2) and Section 2(b)(4)).
-
Protecting innovation incentives: By addressing policies that mandate artificially low prices, the bill aims to prevent the reduction of global incentives to invest in the development of new medicines (Section 2(a)(2) and Section 2(b)(2)).
-
Protecting consumers and manufacturers: The establishment of a Chief Pharmaceutical Trade Negotiator is intended to provide a vigorous advocate for United States consumers and pharmaceutical manufacturers (Section 3(a)(2)).
-
Addressing unfair cost shifts: The bill seeks to prevent foreign countries from shifting the costs of developing new treatments onto United States patients and taxpayers (Section 2(b)(3)).
Potential Negative Impacts for People
- Threats to treatment access: The bill notes that existing foreign price controls threaten to restrict access to new treatments and cures for United States patients and consumers (Section 2(a)(2)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Education And Technology
- Improves Intellectual Property Fairness+7Increases Scientific Research Funding+4
- Economy And Finance
- Improves Consumer Protection+5Improves Fiscal Responsibility+5
- Demographic And Interest Groups
- Good For Business Owners+7
- Governance And Ideology
- Increases Federal Power+4Improves Government Transparency+3
- Healthcare
- Improves Healthcare Access+5
- National Security And Foreign Policy
- Improves International Trade+4Improves International Alliances-2
- 7/21/2026
- 1 Cosponsor added.
- 4/20/2026
- 1 Cosponsor added.
- 3/27/2026
- 1 Cosponsor added.
- 8/5/2025
- 1 Cosponsor added.
- 7/29/2025
- Referred to the House Committee on Ways and Means.
- 4 Cosponsors added.
- Introduced in House
Vern BuchananRepublican · Florida
James BairdRepublican · Indiana
Charles FleischmannRepublican · Tennessee
Carol MillerRepublican · West Virginia
Gregory MurphyRepublican · North Carolina
Nathaniel MoranRepublican · Texas
W. SteubeRepublican · Florida
Claudia TenneyRepublican · New York